Opthea has discontinued development of sozinibercept in wet age-related macular degeneration, according to a press release.

ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea and DFA Investors agreed to terminate both COAST and ShORe trials ...

The little hope left for Opthea shareholders has been crushed after the biotech said a second late-stage trial of its eye ...

Opthea Limited (CKDXF – Research Report) received a Sell rating and a A$0.05 price target from Bell Potter analyst Thomas Wakim yesterday. The ...

Opthea said it agreed with the investors in its development funding agreement to end development of sozinibercept in wet AMD, and that the move wouldn't constitute a termination event under the ...

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

Opthea (OPT) announced updates on its Phase 3 clinical program, including the termination of COAST and accelerated topline results from its ...

Biotechnology firm Opthea has warned investors its solvency is in question after the failure of a major clinical trial into ...

Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...